The President & CEO of Bellerophon (NASDAQ: BLPH) is Buying Shares

By George MacDonald

Today, the President & CEO of Bellerophon (NASDAQ: BLPH), Jonathan Peacock, bought shares of BLPH for $6,800.

In addition to Jonathan Peacock, 9 other BLPH executives reported Buy trades in the last month. Jonathan Peacock increased his holding by 2.3% to a total of $2.19.

The company has a one year high of $9.72 and a one year low of $1.20. Currently, Bellerophon has an average volume of 8,511.

Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $9.33, reflecting a -86.6% downside. Starting in July 2015, BLPH received 8 Buy ratings in a row. Three different firms, including Cowen & Co. and FBR Capital, currently also have a Buy rating on the stock.

Looking at blogger coverage of BLPH, there is a 100% Bullish tendency on the stock, in relation to a 75% average bullish tendency within the Healthcare sector.

Over the last 3 months, the insider sentiment on Bellerophon has been neutral based on 21 corporate insider transactions. This sentiment is slightly lower than the average sector sentiment of insiders.

Bellerophon Therapeutics, Inc. engages in developing products at the intersection of drugs and devices. Its products are using in the treatment of cardiopulmonary and cardiac diseases. The company currently operates through the Research & Development Business. It is engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Hampton, NJ.